Cancer Immunomodulators Market & Pipeline Insight 2020
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Immune system has developed myriad of techniques for preventing progression and proliferation of infectious diseases in the body. Different immunocytes vary in qualitative/quantitative interaction with different components due to which variable immune reactions are produced. The intensity of these interactions could be modified with the help of immunomodulators. They could be natural occurring or synthetically derived molecule used for modulating activities of immune system. Immunomodulators have ability to augment or reduce immune reactions depending upon nature of ailment. In their presence, immune system produces those molecules which increase the rate of reaction and increases immunity. On the other hand, these molecules may reduce the effect of immune system in order to alleviate the patients’ medical condition.
Investigators have been able to identify their clinical applicability in various diseases due to which various immunomodulator based products are entering in global market. They are continuously changing due to which they may be tweaked according to medical necessity. Owing to multiple effects on immune system, sometimes they may be observed in overlapping drug categories. Immunomodulators present in body may undergo biochemical and biophysical changes and become overactive to target own components. This case has been widely observed in autoimmune diseases where multiple issues appear without any apparent reasons. On the other hand, effective defense against removal of cancerous cells is lost due to which pharmacological preparation has to be administered. Immunomodulators are widely used in these and other categories as they proved to have superior pharmacological efficacy along with minimum adverse effects.
Immunomodulators can bring changes in immune system due to which changes in immunochemistry are observed and they could be customized to alter programming of immune system. As a result, pharmacological benefits of immunomodulators are being explored by investigators in clinical trials. Their oncological applications are being studied and various drug candidates are at different stages of clinical trials which would be commercialized in coming years. New modalities are also being discovered by investigators to increase the potency, long-term cancer remission and administration in various cancer indications. In this way, cancer immunomodulators are expected to offer better medical care to cancer patients. Few immunomodulators drugs for various cancer indications have been introduced in market and they are also expected to increase number in coming years.
Demand for novel immunomodulators having higher pharmacological benefits is escalating rapidly across the globe. Pharmaceutical companies have recognized their marketing potential of due to which higher investments are being made in research and development category. They are highly compatible in nature and easily customized due to which they could be designed according to the necessities of drug development program. Moreover, their clinical pipeline is expected to become strong due to increased rate of innovations. In coming years, new immunomodulators would be available in market that would be able to fulfill the high unmet medical demand. Increasing cancer incidences has created burgeoning pressure on pharmaceutical companies to introduce them promptly in global market. Their development may take time which is expected to be solved by technological advancements and increased knowledge about their mechanisms.
'Cancer Immunomodulators Market & Pipeline Insight 2020' Report Highlights:
Immune system has developed myriad of techniques for preventing progression and proliferation of infectious diseases in the body. Different immunocytes vary in qualitative/quantitative interaction with different components due to which variable immune reactions are produced. The intensity of these interactions could be modified with the help of immunomodulators. They could be natural occurring or synthetically derived molecule used for modulating activities of immune system. Immunomodulators have ability to augment or reduce immune reactions depending upon nature of ailment. In their presence, immune system produces those molecules which increase the rate of reaction and increases immunity. On the other hand, these molecules may reduce the effect of immune system in order to alleviate the patients’ medical condition.
Investigators have been able to identify their clinical applicability in various diseases due to which various immunomodulator based products are entering in global market. They are continuously changing due to which they may be tweaked according to medical necessity. Owing to multiple effects on immune system, sometimes they may be observed in overlapping drug categories. Immunomodulators present in body may undergo biochemical and biophysical changes and become overactive to target own components. This case has been widely observed in autoimmune diseases where multiple issues appear without any apparent reasons. On the other hand, effective defense against removal of cancerous cells is lost due to which pharmacological preparation has to be administered. Immunomodulators are widely used in these and other categories as they proved to have superior pharmacological efficacy along with minimum adverse effects.
Immunomodulators can bring changes in immune system due to which changes in immunochemistry are observed and they could be customized to alter programming of immune system. As a result, pharmacological benefits of immunomodulators are being explored by investigators in clinical trials. Their oncological applications are being studied and various drug candidates are at different stages of clinical trials which would be commercialized in coming years. New modalities are also being discovered by investigators to increase the potency, long-term cancer remission and administration in various cancer indications. In this way, cancer immunomodulators are expected to offer better medical care to cancer patients. Few immunomodulators drugs for various cancer indications have been introduced in market and they are also expected to increase number in coming years.
Demand for novel immunomodulators having higher pharmacological benefits is escalating rapidly across the globe. Pharmaceutical companies have recognized their marketing potential of due to which higher investments are being made in research and development category. They are highly compatible in nature and easily customized due to which they could be designed according to the necessities of drug development program. Moreover, their clinical pipeline is expected to become strong due to increased rate of innovations. In coming years, new immunomodulators would be available in market that would be able to fulfill the high unmet medical demand. Increasing cancer incidences has created burgeoning pressure on pharmaceutical companies to introduce them promptly in global market. Their development may take time which is expected to be solved by technological advancements and increased knowledge about their mechanisms.
'Cancer Immunomodulators Market & Pipeline Insight 2020' Report Highlights:
- Introduction & Need of Cancer Immunomodulators
- Cancer Immunomodulators Mechanism
- Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase
- Cancer Immunomodulators Clinical Pipeline: 747 Cancer Immunomodulators Drugs
- Majority Cancer Immunomodulators in Preclinical Phase: 300 Marketed Cancer Immunomodulators Clinical Insight
- Marketed Cancer Immunomodulators: 47
- Cancer Immunomodulators Drug Patent Analysis
1. INTRODUCTION TO CANCER IMMUNOMODULATORS
2. CANCER IMMUNOMODULATORS MECHANISM
3. NEED FOR IMMUNOMODULATORS IN CANCER THERPAY
4. GLOBAL CANCER IMMUNOMODULATORS MARKET OVERVIEW
4.1 Current Market Scenario
4.2 Cancer Immunomodulators Clinical Pipeline Analysis
5. CANCER IMMUNOMODULATORS MARKET FAVORABLE PARAMETERS
5.1 Research & Development
5.2 Escalating Cancer Incidences
5.3 Advances in Recombinant DNA Technology
5.4 Identification of New Pathways
5.5 Demand for Better Therapeutics
6. CANCER IMMUNOMODULATORS MARKET CHALLENGES
7. CANCER IMMUNOMODULATORS MARKET FUTURE OUTLOOK
8. CANCER IMMUNOMODULATORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Unknown
8.2 Research
8.3 Preclinical
8.4 Clinical
8.5 Phase-I
8.6 Phase-I/II
8.7 Phase-II
8.8 Phase-II/III
8.9 Phase-III
8.10 Preregistration
8.11 Registered
9. MARKETED CANCER IMMUNOMODULATORS CLINCIAL INSIGHT
10. COMPETITIVE LANDSCAPE
10.1 3M Pharmaceuticals
10.2 AbGenomics Corporation
10.3 Advaxis
10.4 Amgen
10.5 ANI Pharmaceuticals
10.6 Argos Therapeutics
10.7 AVAX Technologies
10.8 Baxter International
10.9 Biosidus
10.10 Biovest International
10.11 Bristol Myers Squibb
10.12 Celgene Corporation
10.13 Curadev
10.14 GlaxoSmithKline
10.15 Gradalis
10.16 Incyte
10.17 Intas Biopharmaceuticals
10.18 iTeos Therapeutics
10.19 Kyorin Pharmaceutical
10.20 Liponova
10.21 MedImmune
10.22 Merck
10.23 Mologen
10.24 NewLink Genetics Corporation
10.25 Northwest Biotherapeutics
10.26 Novartis
10.27 Peregrine Pharmaceuticals
10.28 Pfizer
10.29 Reliance Life Sciences
10.30 Roche
10.31 Sanofi
10.32 Toray
10.33 Vaccinogen
LIST OF FIGURE
Figure 1-1: Functions of Immunomodulators
Figure 1-2: Benefits of Immunomodulators
Figure 1-3: Limitations of Immunomodulators
Figure 2-1: Mechanism of Thalidomide
Figure 2-2: Mechanism of Lenalidomide In Vivo
Figure 2-3: Mechanism of Lenalidomide In Vitro
Figure 2-4: Mechanism of Pomalidomide
Figure 2-5: Mechanism of IDO Inhibitor
Figure 2-6: Mechanism of TDO Inhibitor
Figure 2-7: Mechanism of dSLIM immunomodulator
Figure 4-1: Global Immunomodulators Market (US$ Billion), 2014-2020
Figure 4-3: Cancer Immunomodulators Pipeline by Phase (%), 2015
Figure 4-4: Cancer Immunomodulators Pipeline by Phase (Number), 2015
Figure 5-1: Cancer Immunomodulators Market Favorable Parameters
Figure 5-2: Cancer Immunomodulators Market Challenges
Figure 9-1: AbGenomics-Clinical Pipeline
Figure 9-2: Argos Therapeutics Clinical Pipeline
Figure 9-3: Gradalis Clinical Pipeline
2. CANCER IMMUNOMODULATORS MECHANISM
3. NEED FOR IMMUNOMODULATORS IN CANCER THERPAY
4. GLOBAL CANCER IMMUNOMODULATORS MARKET OVERVIEW
4.1 Current Market Scenario
4.2 Cancer Immunomodulators Clinical Pipeline Analysis
5. CANCER IMMUNOMODULATORS MARKET FAVORABLE PARAMETERS
5.1 Research & Development
5.2 Escalating Cancer Incidences
5.3 Advances in Recombinant DNA Technology
5.4 Identification of New Pathways
5.5 Demand for Better Therapeutics
6. CANCER IMMUNOMODULATORS MARKET CHALLENGES
7. CANCER IMMUNOMODULATORS MARKET FUTURE OUTLOOK
8. CANCER IMMUNOMODULATORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Unknown
8.2 Research
8.3 Preclinical
8.4 Clinical
8.5 Phase-I
8.6 Phase-I/II
8.7 Phase-II
8.8 Phase-II/III
8.9 Phase-III
8.10 Preregistration
8.11 Registered
9. MARKETED CANCER IMMUNOMODULATORS CLINCIAL INSIGHT
10. COMPETITIVE LANDSCAPE
10.1 3M Pharmaceuticals
10.2 AbGenomics Corporation
10.3 Advaxis
10.4 Amgen
10.5 ANI Pharmaceuticals
10.6 Argos Therapeutics
10.7 AVAX Technologies
10.8 Baxter International
10.9 Biosidus
10.10 Biovest International
10.11 Bristol Myers Squibb
10.12 Celgene Corporation
10.13 Curadev
10.14 GlaxoSmithKline
10.15 Gradalis
10.16 Incyte
10.17 Intas Biopharmaceuticals
10.18 iTeos Therapeutics
10.19 Kyorin Pharmaceutical
10.20 Liponova
10.21 MedImmune
10.22 Merck
10.23 Mologen
10.24 NewLink Genetics Corporation
10.25 Northwest Biotherapeutics
10.26 Novartis
10.27 Peregrine Pharmaceuticals
10.28 Pfizer
10.29 Reliance Life Sciences
10.30 Roche
10.31 Sanofi
10.32 Toray
10.33 Vaccinogen
LIST OF FIGURE
Figure 1-1: Functions of Immunomodulators
Figure 1-2: Benefits of Immunomodulators
Figure 1-3: Limitations of Immunomodulators
Figure 2-1: Mechanism of Thalidomide
Figure 2-2: Mechanism of Lenalidomide In Vivo
Figure 2-3: Mechanism of Lenalidomide In Vitro
Figure 2-4: Mechanism of Pomalidomide
Figure 2-5: Mechanism of IDO Inhibitor
Figure 2-6: Mechanism of TDO Inhibitor
Figure 2-7: Mechanism of dSLIM immunomodulator
Figure 4-1: Global Immunomodulators Market (US$ Billion), 2014-2020
Figure 4-3: Cancer Immunomodulators Pipeline by Phase (%), 2015
Figure 4-4: Cancer Immunomodulators Pipeline by Phase (Number), 2015
Figure 5-1: Cancer Immunomodulators Market Favorable Parameters
Figure 5-2: Cancer Immunomodulators Market Challenges
Figure 9-1: AbGenomics-Clinical Pipeline
Figure 9-2: Argos Therapeutics Clinical Pipeline
Figure 9-3: Gradalis Clinical Pipeline
